Event Details

While increasing pressure on healthcare brought about by China's exit from zero-Covid was foreseeable, the rapidly surging caseload nationwide has put an overwhelming strain on the country's hospitals and medicine supplies, especially in lower-tier cities and rural areas. At the same time, China's aging population is intensifying concerns about higher medical costs and the sustainability of pensions. The latest Global Health Expenditure Database of the WHO shows that China ranks 86th in terms of total health spending per capita in 2020, well below some lesser developed countries in Southeast Asia and Latin America. All of this is strengthening calls for further substantial reforms to the country's healthcare system.

What is the current outlook for China's healthcare system and its reform? Are there emerging business opportunities in the healthcare sector in the Chinese market? How should companies respond to China's centralised volume-based procurement programme to stay in the market and maintain a certain profit margin?

Join business leaders and industry experts for an in-depth discussion of these questions. Please bring your own insights to the table for what is sure to be a lively conversation.

Please note that this event is limited to senior-level executives and per invitation only. If you are not an existing member of The Economist Intelligence Corporate Network, but would like to learn how you can attend our events, please contact us.


12:00 PM - 12:30 PM
Registration & Network
12:30 PM - 2:00 PM
Luncheon and Discussions


  • Anita Wei (VP, Government Affairs, Danaher China; Chair of AmCham Shanghai Healthcare Committee; Co-Founder of Carnation Project, CDRF)

    Anita Wei

    VP, Government Affairs, Danaher China; Chair of AmCham Shanghai Healthcare Committee; Co-Founder of Carnation Project, CDRF

    Anita Wei is the Vice President of Government Affairs for Danaher China and a member of Danaher China Leadership Team (CLT). She reports to Global VP/Group President of Danaher China.

    Anita is taking the lead in developing and maintaining central and local government relations, managing cooperation programs with government, enhancing Danaher corporate branding in China. She also responsible for policy monitoring and analysis, evidence-based value access as well as industry alliance for policy shaping. She and her team are currently mainly responsible for supporting all Operation Companies (OpCos) across four platforms within Danaher.

    Anita serves as the Chair of AmCham Shanghai Healthcare Committee and Executive Committee Delegate of AdvaMed China. She is actively involved in industry-related affairs.

    Prior to joining Danaher, Anita was the Vice President Public Affairs and Communications for BD Greater China. She was responsible for four teams, including public relations and corporate communications, health economics and value access, policy research and industry advocacy, and central government cooperation. Prior to that, she also worked for Novartis Pharma as Head of Communications for Greater China.

    Anita is also an advocate of diversity and inclusion and has been very active in promoting women's development. She is the co-founder for Carnation Project of China Development and Research Foundation (CDRF), advocating for women health and well-being.

    Anita holds a Bachelor's degree in Economics from University of International Business and Economics and a Master's degree in international Business from the University of Sydney.

    view more
  • Mattie Bekink (China Director of the Economist Intelligence Corporate Network)

    Mattie Bekink

    China Director of the Economist Intelligence Corporate Network

    Mattie Bekink is responsible for the Economist Intelligence Corporate Network’s China strategy, including programme development and client engagement across China.

    Ms Bekink has extensive experience in the public, private and policy sectors. Prior to joining The Economist Group, she was the Executive Director of the Fulbright Commission in the Netherlands. She also ran an eponymous consulting business, advising businesses, universities and non-profit organisations on China policy, strategy, public affairs, and CSR. Ms Bekink practiced law at Skadden, Arps, Slate, Meagher & Flom LLP, has worked with the US-Asia Law Initiative at NYU Law School and the American Bar Association Rule of Law Initiative China Program, and served in the legal department at General Motors China.

    Ms Bekink has a BA in International Relations from Stanford University and a JD from the Georgetown University Law Center.

    view more
  • Dr Alexandre Moreau (Country President at UCB China)

    Dr Alexandre Moreau

    Country President at UCB China

    Alexandre Moreau is UCB China Country President since April 2022. In his role, Alexandre is responsible for delivering on the company’s responsibility to unlock the potential for helping patients in the world’s 2nd largest healthcare market.

    He is also member of the UCB International Markets leadership team, leading UCB China country strategy and operations. From 2018 through 2022, Alexandre had Corporate Vice President responsibilities as UCB Head of Global Epilepsy Unit and UCB Global Strategy Lead for the Osteoporosis therapeutic area. In these roles, Alexandre guided the development of the UCB strategic roadmap, supported the acquisition of Engage Therapeutics Inc. and Zogenix Inc.

    Alexandre is passionate about improving patient care and has 30 years of broad multi-national leadership experience across the value chain. Prior to joining UCB, He served top leading pharmaceutical companies such as Roche-Genentech, Sanofi, Novartis, Novo-Nordisk, Bayer, Astra Zeneca.

    Alexandre is also an entrepreneur. He co-founded Axxelis AG, a management consulting firm based in Switzerland and worked in biotech as CEO and board member. With a strong track-record as a people-first leader, Alexandre has also focused his energy on creating working environment where each individual can show up every day as their authentic self to best serve the interest of people and in particular living with disease.

    Alexandre has a science and business background. He received a Doctorate in Pharmaceutical and Biological Sciences from Rene Descartes University (Paris, Fr), an MBA from La Sorbonne University (Paris, Fr) and graduated from the INSEAD Advanced Management Program (Fontainebleau, Fr) as well as from the General Management Program at Harvard Business School (Cambridge, US).

    view more
  • Wayne Shi (Country Lead and Head of General Medicines for Sanofi Greater China)

    Wayne Shi

    Country Lead and Head of General Medicines for Sanofi Greater China

    Wayne Shi was appointed Country Lead and Head of General Medicines for Sanofi Greater China beginning August 1st, 2022.

    Wayne and his team are fully dedicated to making a positive impact on people’s lives by accelerating the introduction of innovative medicines and making Sanofi’s products accessible to the broadest base of the Chinese population. He is strongly focused on driving digitalization and the go-to-market transformation to best serve the evolving needs of China healthcare, as well as empowering people to bring their best to the workplace.

    Wayne has a deep knowledge of the Chinese healthcare ecosystem. He started his career in the late 1990’s and has held several positions with increasing responsibilities in international pharmaceutical companies. Besides his root in China, Wayne’s experience in the U.K. in a global marketing role brought him deep insight on how Global and Country organisation best collaborate to achieve results.

    Wayne has a bachelor of Traditional Chinese Medicine from the Nanjing University of Traditional Chinese Medicine, China and a Master of Business Management from the Olin Business School, Washington University of St. Louis, United States.

    view more